TY - JOUR
T1 - Remission of Non-Infectious Anterior Scleritis
T2 - Incidence and Predictive Factors
AU - Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study Research Group
AU - Kempen, John H.
AU - Pistilli, Maxwell
AU - Begum, Hosne
AU - Fitzgerald, Tonetta D.
AU - Liesegang, Teresa L.
AU - Payal, Abhishek
AU - Zebardast, Nazlee
AU - Bhatt, Nirali P.
AU - Foster, C. Stephen
AU - Jabs, Douglas A.
AU - Levy-Clarke, Grace A.
AU - Nussenblatt, Robert B.
AU - Rosenbaum, James T.
AU - Sen, H. Nida
AU - Suhler, Eric B.
AU - Thorne, Jennifer E.
N1 - Funding Information:
A. Funding/Support: This study was supported primarily by National Eye Institute Grant EY014943 (Dr. Kempen). Additional support for Dr. Kempen's work was provided by Research to Prevent Blindness and the Paul and Evanina Mackall Foundation. Drs. Kempen was an RPB James S. Adams Special Scholar Award recipient and Dr. Thorne was an RPB Harrington Special Scholar Award recipient during the conduct of the study. Drs. Jabs and Rosenbaum are Research to Prevent Blindness Senior Scientific Investigator Award recipients. Dr. Levy-Clarke and Dr. Nussenblatt previously were supported by and Dr. Sen continues to be supported by intramural funds of the National Eye Institute. None of the sponsors had any role in the design and conduct of the report; collection, management, analysis, and interpretation of the data; nor in the preparation, review, and approval of this manuscript. B. Financial Disclosures: JHK serves as a consultant to Gilead (DSMC Chair) and Santen (study design). C. Contributions of Authors in each of these areas: Design of the Study: JHK, CSF, DAJ, GAL-C, RBN, JTR, EBS. Conduct of the Study: JHK, HB, TDF, TLL, AP, NPB, CSF, DAJ, GAL-C, RBN, JTR, HNS, EBS. Analysis of the Data: JHK, MP. Drafting the Manuscript: JHK. Revising/Approving the Final Version of the Manuscript: All Authors. D. Other Acknowledgments: None.
Funding Information:
A. Funding/Support: This study was supported primarily by National Eye Institute Grant EY014943 (Dr. Kempen). Additional support for Dr. Kempen's work was provided by Research to Prevent Blindness and the Paul and Evanina Mackall Foundation. Drs. Kempen was an RPB James S. Adams Special Scholar Award recipient and Dr. Thorne was an RPB Harrington Special Scholar Award recipient during the conduct of the study. Drs. Jabs and Rosenbaum are Research to Prevent Blindness Senior Scientific Investigator Award recipients. Dr. Levy-Clarke and Dr. Nussenblatt previously were supported by and Dr. Sen continues to be supported by intramural funds of the National Eye Institute. None of the sponsors had any role in the design and conduct of the report; collection, management, analysis, and interpretation of the data; nor in the preparation, review, and approval of this manuscript.
Publisher Copyright:
© 2019
PY - 2021/3
Y1 - 2021/3
N2 - Purpose: To assess how often non-infectious anterior scleritis remits and identify predictive factors. Methods: Our retrospective cohort study at four ocular inflammation subspecialty centers collected data for each affected eye/patient at every visit from center inception (1978, 1978, 1984, 2005) until 2010. Remission was defined as inactivity of disease off all suppressive medications at all visits spanning at least three consecutive months or at all visits up to the last visit (to avoid censoring patients stopping follow-up after remission). Factors potentially predictive of remission were assessed using Cox regression models. Results: During 1,906 years' aggregate follow-up of 832 affected eyes, remission occurred in 214 (170 of 584 patients). Median time-to-remission of scleritis = 7.8 years (95% confidence interval [CI]: 5.7, 9.5). More remissions occurred earlier than later during follow-up. Factors predictive of less scleritis remission included scleritis bilaterality (adjusted hazard ratio [aHR] = 0.46, 95% CI: 0.32-0.65); and diagnosis with any systemic inflammatory disease (aHR = 0.36, 95% CI: 0.23-0.58), or specifically with Rheumatoid Arthritis (aHR = 0.22), or Granulomatosis with Polyangiitis (aHR = 0.08). Statin treatment (aHR = 1.53, 95% CI: 1.03-2.26) within ≤90 days was associated with more remission incidence. Conclusions: Our results suggest scleritis remission occurs more slowly in anterior scleritis than in newly diagnosed anterior uveitis or chronic anterior uveitis, suggesting that attempts at tapering suppressive medications is warranted after long intervals of suppression. Remission is less frequently achieved when systemic inflammatory diseases are present. Confirmatory studies of whether adjunctive statin treatment truly can enhance scleritis remission (as suggested here) are needed.
AB - Purpose: To assess how often non-infectious anterior scleritis remits and identify predictive factors. Methods: Our retrospective cohort study at four ocular inflammation subspecialty centers collected data for each affected eye/patient at every visit from center inception (1978, 1978, 1984, 2005) until 2010. Remission was defined as inactivity of disease off all suppressive medications at all visits spanning at least three consecutive months or at all visits up to the last visit (to avoid censoring patients stopping follow-up after remission). Factors potentially predictive of remission were assessed using Cox regression models. Results: During 1,906 years' aggregate follow-up of 832 affected eyes, remission occurred in 214 (170 of 584 patients). Median time-to-remission of scleritis = 7.8 years (95% confidence interval [CI]: 5.7, 9.5). More remissions occurred earlier than later during follow-up. Factors predictive of less scleritis remission included scleritis bilaterality (adjusted hazard ratio [aHR] = 0.46, 95% CI: 0.32-0.65); and diagnosis with any systemic inflammatory disease (aHR = 0.36, 95% CI: 0.23-0.58), or specifically with Rheumatoid Arthritis (aHR = 0.22), or Granulomatosis with Polyangiitis (aHR = 0.08). Statin treatment (aHR = 1.53, 95% CI: 1.03-2.26) within ≤90 days was associated with more remission incidence. Conclusions: Our results suggest scleritis remission occurs more slowly in anterior scleritis than in newly diagnosed anterior uveitis or chronic anterior uveitis, suggesting that attempts at tapering suppressive medications is warranted after long intervals of suppression. Remission is less frequently achieved when systemic inflammatory diseases are present. Confirmatory studies of whether adjunctive statin treatment truly can enhance scleritis remission (as suggested here) are needed.
UR - http://www.scopus.com/inward/record.url?scp=85081898745&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85081898745&partnerID=8YFLogxK
U2 - 10.1016/j.ajo.2019.03.024
DO - 10.1016/j.ajo.2019.03.024
M3 - Article
C2 - 30951689
AN - SCOPUS:85081898745
SN - 0002-9394
VL - 223
SP - 377
EP - 395
JO - American Journal of Ophthalmology
JF - American Journal of Ophthalmology
ER -